Verastem, Inc. (VSTM)
| Market Cap | 362.04M +11.7% |
| Revenue (ttm) | 49.59M +395.9% |
| Net Income | -193.96M |
| EPS | -2.41 |
| Shares Out | 87.87M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,765,945 |
| Open | 4.240 |
| Previous Close | 4.170 |
| Day's Range | 4.110 - 4.425 |
| 52-Week Range | 3.550 - 11.245 |
| Beta | 0.27 |
| Analysts | Strong Buy |
| Price Target | 16.00 (+288.35%) |
| Earnings Date | Aug 6, 2026 |
About VSTM
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in various cancers; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine ki... [Read more]
Financial Performance
In 2025, Verastem's revenue was $30.91 million, an increase of 209.14% compared to the previous year's $10.00 million. Losses were -$209.47 million, 60.3% more than in 2024.
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for VSTM stock is "Strong Buy." The 12-month stock price target is $16.0, which is an increase of 288.35% from the latest price.
News
Verastem announces safety, efficacy results from RAMP 205 Phase 1b/2a study
Verastem (VSTM) Oncology announced positive updated safety and efficacy results from the RAMP 205 Phase 1b/2a Recommended Phase 2 Dose cohort of 29 patients evaluating avutometinib plus defactinib in ...
Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in First-Line Metastatic Pancreatic Cancer
BOSTON--(BUSINESS WIRE)---- $VSTM #CancerResearch--Verastem Oncology announces updated results from RAMP 205 clinical trial in first-line metastatic pancreatic ductal adenocarcinoma.
Verastem doses first Patient in TARGET-D 201 Phase 2 trial of VS-7375
The company states: “Verastem (VSTM) Oncology announced that the first patient has been dosed in the TARGET-D 201 Phase 2 registration-directed trial evaluating VS-7375, an investigational oral KRAS G...
Verastem Oncology Doses First Patient in TARGET-D 201 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Pancreatic Cancer
BOSTON--(BUSINESS WIRE)---- $VSTM #CRC--Verastem doses first patient in TARGET-D 201, a registration-directed Phase 2 trial of VS-7375 in KRAS G12D-mutated advanced pancreatic cancer.
Verastem Oncology to Host Investor Conference Call and Report Updated Data and Progress Across VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor TARGET-D Clinical Program
BOSTON--(BUSINESS WIRE)---- $VSTM #CRC--Verastem Oncology to report progress across the VS-7375 oral KRAS G12D (ON/OFF) TARGET-D program and updated Phase 1/2 TARGET-D 101 data.
Verastem up 11% at $4.00 after announcing FDA Fast Track designation for VS-7375
16:21 EDT Verastem (VSTM) up 11% at $4.00 after announcing FDA Fast Track designation for VS-7375
Verastem announces FDA Fast Track designation for VS-7375
The company states: “Verastem (VSTM) announced that the U.S. Food and Drug Administration has granted Fast Track Designation to VS-7375, an oral and potential best-in-class investigational selective K...
Verastem Oncology Announces U.S. FDA Fast Track Designation for VS-7375, an Oral and Potential Best-in-Class Investigational KRAS G12D (ON/OFF) Inhibitor for the Treatment of KRAS G12D-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
BOSTON--(BUSINESS WIRE)---- $VSTM #CRC--FDA grants Fast Track designation to VS-7375, an oral investigational KRAS G12D inhibitor, for locally advanced or metastatic KRAS G12D-mutated NSCLC.
Verastem Transcript: Jefferies Global Healthcare Conference 2026
AVMAPKI FAKZYNJA CO-PACK continues to grow, with commercial efforts focused on earlier therapy use and patient retention. The KRAS G12D inhibitor shows strong promise in phase II, with a favorable safety profile and regulatory momentum. Cash reserves support operations into 2027.
Verastem Oncology to Present at Jefferies Healthcare Conference
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its ...
Verastem appoints Michael Bailey to board of directors
Verastem (VSTM) Oncology announced the appointment of Michael Bailey to its Board of Directors. The Company also announced that Robert Gagnon stepped down from the Board following the end of…
Verastem Oncology Appoints Michael P. Bailey to its Board of Directors
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the appoi...
Verastem Transcript: RBC Capital Markets Global Healthcare Conference 2026
VS-7375 is advancing in the U.S. with promising safety and efficacy, leveraging learnings from Chinese trials and higher dosing. Regulatory strategy includes separate phase II protocols and phase III plans, while commercial efforts for Avmapki Fakzynja focus on education, analytics, and expanding patient access.
Verastem Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference
Focused on RAS/MAPK cancers, the company has achieved accelerated approval for its LGSOC therapy and is advancing a KRAS G12D inhibitor with strong early results. Phase II trials in multiple cancers begin in June, with label expansion and pivotal data readouts expected next year.
Verastem price target lowered to $14 from $16 at Mizuho
Mizuho analyst Graig Suvannavejh lowered the firm’s price target on Verastem (VSTM) to $14 from $16 and keeps an Outperform rating on the shares. The firm updated the company’s model…
Verastem Oncology to Present at Upcoming Investor Conferences
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its ...
Verastem price target lowered to $18 from $19 at BTIG
BTIG lowered the firm’s price target on Verastem (VSTM) to $18 from $19 and keeps a Buy rating on the shares after its Q1 results. The revamped commercial efforts should…
On World Ovarian Cancer Day, LGSOC Resource Guide Launches to Support People Living with Low-Grade Serous Ovarian Cancer
BOSTON--(BUSINESS WIRE)--Today, STAAR Low-Grade Serous Ovarian Cancer Foundation, Not These Ovaries, and Verastem Oncology announced the launch of the LGSOC Resource Guide, a unique resource designed ...
Verastem price target raised to $18 from $16 at Alliance Global
Alliance Global raised the firm’s price target on Verastem (VSTM) to $18 from $16 and keeps a Buy rating on the shares after the company’s Q1 earnings report included detailing…
Verastem reports Q1 adjusted EPS (43c), consensus (47c)
Reports Q1 revenue $18.67M, consensus $21.39M. “As we mark the one-year anniversary of the FDA-approval of AVMAPKI FAKZYNJA CO-PACK for KRAS-mutated recurrent low-grade serous ovarian cancer, I am inc...
Verastem Earnings Call Transcript: Q1 2026
Q1 2026 saw $18.7M in net product revenue and expanding prescriber adoption, with the LGSOC franchise expected to be self-sustaining in H2 2026. R&D advanced with new phase II trials for VS-7375, and cash runway extends into H1 2027.
Verastem Earnings release: Q1 2026
Verastem released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Verastem Quarterly report: Q1 2026
Verastem has published its Q1 2026 quarterly earnings report on May 7, 2026.
Verastem Slides: Q1 2026
Verastem has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.
Verastem Oncology Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today reported financial ...